2-phenyl-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine | 450353-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-phenyl-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine
• 英文别名: AF-399/13565054；2-phenyl-N-[3-(trifluoromethyl)phenyl]quinazolin-4-amine
• CAS: 450353-74-9
• 化学式: C₂₁H₁₄F₃N₃
• mdl: MFCD02069156
• 分子量: 365.357
• InChiKey: IUPGPZVLBBNEIG-UHFFFAOYSA-N

物化性质

• 沸点：
  402.0±45.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-苯基-4-[3H]喹唑啉酮 在 三氯氧磷 作用下， 以 异丙醇 为溶剂， 反应 16.08h， 生成 2-phenyl-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine
  参考文献：
  名称：

  喹唑啉衍生物作为有效抗克鲁氏锥虫药物的合成，2D-QSAR研究和生物学评价

  摘要：

  背景：恰加斯病感染了全世界约700万人。目前只有两种药物可用于治疗这种寄生虫病，即苯并尼达唑（Bzn）和硝呋替莫（Nfx）。两种药物在该疾病的慢性期均具有有限的疗效。因此，持续的研究是迫切需要以发现新颖的治疗选择。 目的：开发更安全，更有效的治疗性抗-T。Cruzi药物仍然是锥虫杀伤性化疗的主要目标。 方法：研究了一组喹唑啉酮和喹唑啉衍生物作为锥虫杀螨剂的合成，2D-QSAR和类药物理化性质。体外针对克氏锥虫（图拉胡恩（Tulahuen）菌株，Tul 2原种）的表鞭毛纲动物和血流类锥鞭毛纲动物筛选了所有化合物。 结果：在合成和测试的34种化合物中，有6种化合物（5a，5b，9b，9h，13f和13p）对前鞭毛体和三鞭毛体均显示出显着活性，而对Vero细胞无毒性。 结论：这些喹唑啉酮和喹唑啉衍生物的抗原生动物活性代表了针对旨在开发查加斯病的新型化学疗法的药物化学程序的有趣起点。

  DOI：

  10.2174/1573406414666181005145042

文献信息

• 4-Substituted-2-phenylquinazolines as inhibitors of BCRP
  作者：Kapil Juvale、Michael Wiese

  DOI：10.1016/j.bmcl.2012.08.024

  日期：2012.11

  We investigated several 2-phenylquinazolines with different substitutions at position 4 for their BCRP inhibition. Compounds with phenyl ring attached via an amine-containing linker at position 4 were found to be potent inhibitors of BCRP. In general compounds with meta substitution of phenyl ring at position 4 were found to have higher inhibitory effect, compound 12 being the most potent and selective towards BCRP. (C) 2012 Elsevier Ltd. All rights reserved.
• Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)
  作者：Kapil Juvale、Jennifer Gallus、Michael Wiese

  DOI：10.1016/j.bmc.2013.10.007

  日期：2013.12

  Chemotherapy is one of the major forms of cancer treatment. Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment. Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance. Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified. In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compounds. Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship analysis for these compounds. It was found that compounds bearing a phenyl substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent. On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies. The most potent compounds were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance. Compound 20, an anilinoquinazoline bearing a phenyl ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio. The most active compounds from each variation were also investigated for their effect on BCRP expression. It was found that compound 20 has no significant effect on BCRP expression, while compound 31 decreased the surface BCRP expression. The only difference in the two compounds was the presence of a 3,4-dimethoxyphenyl ring in compound 31 instead of phenyl substitution at position 2 of the quinazoline moiety. From the study of all target compounds, compound 20 was the most prominent compound having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known. Compound 20 was also found to be selective towards BCRP with a very high therapeutic ratio. (C) 2013 Elsevier Ltd. All rights reserved.
• Synthesis, 2D-QSAR Studies and Biological Evaluation of Quinazoline Derivatives as Potent Anti-Trypanosoma cruzi Agents
  作者：Mariela Bollini、Ana M. Bruno、María E. Niño、Juan J. Casal、Leandro D. Sasiambarrena、Damián A.G. Valdez、Leandro Battini、Vanesa R. Puente、María E. Lombardo

  DOI：10.2174/1573406414666181005145042

  日期：2019.4.12

  disease. Therefore, continuous research is an urgent need so as to discover novel therapeutic alternatives. Objective: The development of safer and more efficient therapeutic anti-T. cruzi drugs continues to be a major goal in trypanocidal chemotherapy. Method: Synthesis, 2D-QSAR and drug-like physicochemical properties of a set of quinazolinone and quinazoline derivatives were studied as trypanocidal

  背景：恰加斯病感染了全世界约700万人。目前只有两种药物可用于治疗这种寄生虫病，即苯并尼达唑（Bzn）和硝呋替莫（Nfx）。两种药物在该疾病的慢性期均具有有限的疗效。因此，持续的研究是迫切需要以发现新颖的治疗选择。 目的：开发更安全，更有效的治疗性抗-T。Cruzi药物仍然是锥虫杀伤性化疗的主要目标。 方法：研究了一组喹唑啉酮和喹唑啉衍生物作为锥虫杀螨剂的合成，2D-QSAR和类药物理化性质。体外针对克氏锥虫（图拉胡恩（Tulahuen）菌株，Tul 2原种）的表鞭毛纲动物和血流类锥鞭毛纲动物筛选了所有化合物。 结果：在合成和测试的34种化合物中，有6种化合物（5a，5b，9b，9h，13f和13p）对前鞭毛体和三鞭毛体均显示出显着活性，而对Vero细胞无毒性。 结论：这些喹唑啉酮和喹唑啉衍生物的抗原生动物活性代表了针对旨在开发查加斯病的新型化学疗法的药物化学程序的有趣起点。